- In its Q2 earnings release, Endo Health Solutions (NASDAQ:ENDP) says previously announced plans to cut costs are "on track" and a "process" has been launched to explore strategic alternatives for its HealthTronics business.
- Other Q2 takeaways: Opana ER sales fall 38% Y/Y. Q1 2012 stock outs resulted in higher shipments in last year's Q2, so this was probably a tough compare, although the company said last quarter it was factoring in a 20% Y/Y drop in Opana ER net revenues for the full year, so sales may be coming in lighter than expected. Also: a non-AB generic launched earlier this year.
- Other products' Y/Y sales growth: Lidoderm, 1%; Voltaren, -2%; Fortesta, +154%.
- FY13 outlook revised lower: Adjusted EPS of $4.25-4.55 on revenue of $2.7-2.8B.